Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinsons Disease: a Multi-center Placebo-controlled Trial.
Phase of Trial: Phase IV
Latest Information Update: 05 Mar 2019
Price : $35 *
At a glance
- Drugs Rivastigmine (Primary)
- Indications Hallucinations; Parkinson's disease
- Focus Therapeutic Use
- Acronyms CHEVAL
- 04 Oct 2018 Status changed from recruiting to discontinued due to slow enrollment and insufficient funds
- 04 Jan 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
- 04 Jan 2018 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2021.